Citadel Advisors
MLYS icon

Citadel Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Citadel Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Buy
73,600
+38,400
+109% +$1.13M ﹤0.01% 6071
2025
Q4 		$1.28M Sell
35,200
-16,700
-32% -$670K ﹤0.01% 6874
2025
Q3 		$1.97M Buy
+51,900
New +$1.12M ﹤0.01% 6100
2025
Q2 		– Sell
-52,200
Closed -$829K – 14091
2025
Q1 		$829K Buy
+52,200
New +$600K ﹤0.01% 7367
2024
Q4 		– Sell
-4,800
Closed -$58.1K – 15054
2024
Q3 		$58.1K Buy
4,800
+3,200
+200% +$38.7K ﹤0.01% 11742
2024
Q2 		$18.7K Sell
1,600
-4,700
-75% -$59.2K ﹤0.01% 12700
2024
Q1 		$81.3K Buy
+6,300
New +$77.8K ﹤0.01% 11632

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Citadel Advisors's MLYS Position: Q1 2026 in Review

Citadel Advisors increased its Mineralys Therapeutics (MLYS) stake by 50% in Q1 2026, buying an estimated $5.87M and bringing the position to 600,041 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Citadel Advisors first reported a position in MLYS in Q1 2023 and has held it in 11 quarters since. The position peaked at $78.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Citadel Advisors held 600,041 shares of Mineralys Therapeutics worth $16.3M as of Q1 2026.
  • Citadel Advisors bought 200,122 Mineralys Therapeutics shares in Q1 2026, an estimated $5.87M.
  • Mineralys Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2593 holding.
  • Citadel Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Citadel Advisors's Mineralys Therapeutics position peaked at $78.4M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.